Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Adenosine Diphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.80 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.80 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.80 |
| ▸ | SRC | P12931 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.80 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.80 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.80 |
| ▸ | LDHA | P00338 | 1/20 | 0.80 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.80 |
| ▸ | FBP1 | P09467 | 1/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.80 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.80 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.80 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Diphosphate SCHEMBL29352453 | 1.00 | P2RY1 (0.80) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Diphosphate SCHEMBL30936537 | 0.99 | P2RY1 (0.79) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL3040417 | 0.98 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL30522306 | 0.98 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Diphosphate SCHEMBL5498278 | 0.98 | P2RY1 (0.80) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL30786396 | 0.97 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL3332142 | 0.97 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL27783353 | 0.97 | P2RY1 (0.76) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL27531093 | 0.96 | P2RY1 (0.75) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 | |
| Adenosine Triphosphate SCHEMBL29352529 | 0.96 | P2RY1 (0.78) | P2RY1P2RY2P2RY11SRCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113957121-B | Urea determination kit | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 2024-04-26 | — | — | CN | claimed |
| CN-113957121-A | Urea determination kit | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 2022-01-21 | — | — | CN | claimed |
| US-6255291-B1 | MIXTURE OF ALANINE, ADENOSINE COMPOUND, RIBOSE COMPOUND, ASCORBIC ACID AND NICOTINIC ACID | PEREGRINE PHARMACEUTICALS, INC. | 2001-07-03 | — | — | US | claimed |
| CN-113957121-B | Urea determination kit | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 2024-04-26 | — | — | CN | disclosed |
| CN-113957121-B | Urea determination kit | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 2024-04-26 | — | — | CN | disclosed |
| US-20240109925-A1 | Enhanced Anti-Proliferative and Antitumor Immune Effects of Mitochondria-Targeted Hydroxyurea | AIX-MARSEILLE UNIVERSITE (FR) | 2024-04-04 | — | — | US | disclosed |
| CN-113957121-A | Urea determination kit | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 2022-01-21 | — | — | CN | disclosed |
| CN-113957121-A | Urea determination kit | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 2022-01-21 | — | — | CN | disclosed |
| CN-103173519-B | Kit for detecting creatine jubase by enzyme method and preparation method | SHANGHAI FOSUN PHARM GROUP CO | 2014-07-02 | — | — | CN | disclosed |
| CN-103173519-A | Kit for detecting creatine jubase by enzyme method and preparation method | SHANGHAI FOSUN PHARM GROUP CO | 2013-06-26 | — | — | CN | disclosed |
| US-20120156278-A1 | SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE | CASCADE MEDICAL ENTERPRISES, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20090258056-A1 | SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE | CASCADE MEDICAL ENTERPRISES, LLC (US) | 2009-10-15 | — | — | US | disclosed |
| US-20080199513-A1 | SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE | CASCADE MEDICAL ENTERPRISES, LLC (US) | 2008-08-21 | — | — | US | disclosed |
| US-6255291-B1 | MIXTURE OF ALANINE, ADENOSINE COMPOUND, RIBOSE COMPOUND, ASCORBIC ACID AND NICOTINIC ACID | PEREGRINE PHARMACEUTICALS, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0967984-A1 | COMPOSITION AND METHOD FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS RESULTING IN CHRONIC CONDITIONS | Peregrine Pharmaceutical, Inc. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998046206-A1 | SKIN CREAM COMPOSITION | PEREGRINE PHARMACEUTICAL, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998039013-A1 | COMPOSITION AND METHOD FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS RESULTING IN CHRONIC CONDITIONS | PEREGRINE PHARMACEUTICAL, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109925-A1 | Enhanced Anti-Proliferative and Antitumor Immune Effects of Mitochondria-Targeted Hydroxyurea | MAVS, TUFM, SHMT2 | P2RY1 527/4885P2RY2 968/4885P2RY11 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.